JP5089400B2 - 遺伝子 - Google Patents

遺伝子 Download PDF

Info

Publication number
JP5089400B2
JP5089400B2 JP2007549327A JP2007549327A JP5089400B2 JP 5089400 B2 JP5089400 B2 JP 5089400B2 JP 2007549327 A JP2007549327 A JP 2007549327A JP 2007549327 A JP2007549327 A JP 2007549327A JP 5089400 B2 JP5089400 B2 JP 5089400B2
Authority
JP
Japan
Prior art keywords
sequence
cell
cells
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007549327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526200A5 (enExample
JP2008526200A (ja
Inventor
ファング ウォン，チー
ゲック シム ヤップ，ミランダ
Original Assignee
エージェンシー フォー サイエンス、テクノロジー アンド リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エージェンシー フォー サイエンス、テクノロジー アンド リサーチ filed Critical エージェンシー フォー サイエンス、テクノロジー アンド リサーチ
Publication of JP2008526200A publication Critical patent/JP2008526200A/ja
Publication of JP2008526200A5 publication Critical patent/JP2008526200A5/ja
Application granted granted Critical
Publication of JP5089400B2 publication Critical patent/JP5089400B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2007549327A 2004-12-30 2005-12-28 遺伝子 Expired - Fee Related JP5089400B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64033304P 2004-12-30 2004-12-30
US60/640,333 2004-12-30
PCT/SG2005/000433 WO2006071200A2 (en) 2004-12-30 2005-12-28 Chinese hamster apoptosis-related genes

Publications (3)

Publication Number Publication Date
JP2008526200A JP2008526200A (ja) 2008-07-24
JP2008526200A5 JP2008526200A5 (enExample) 2011-12-01
JP5089400B2 true JP5089400B2 (ja) 2012-12-05

Family

ID=36615341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007549327A Expired - Fee Related JP5089400B2 (ja) 2004-12-30 2005-12-28 遺伝子

Country Status (9)

Country Link
US (5) US7846894B2 (enExample)
EP (6) EP2298888A1 (enExample)
JP (1) JP5089400B2 (enExample)
KR (1) KR20070082597A (enExample)
CN (3) CN101133156A (enExample)
AU (1) AU2005322686B2 (enExample)
IL (1) IL183361A0 (enExample)
SG (1) SG158841A1 (enExample)
WO (1) WO2006071200A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2825191B1 (en) 2012-03-16 2019-08-28 University Health Network Soluble toso protein and its use in treating autoimmune disorders
EP2674495A1 (en) * 2012-06-14 2013-12-18 Sanofi CHO expression system
WO2014068048A1 (en) * 2012-11-05 2014-05-08 Celonic Ag Expression system
CA2917077A1 (en) 2013-07-03 2015-01-08 University Health Network Antibodies to toso
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107630038A (zh) * 2017-09-15 2018-01-26 浙江大学 提高老年大鼠骨髓间充质干细胞移植后生存能力的方法
WO2019180607A1 (en) * 2018-03-19 2019-09-26 Centre For Cellular And Molecular Platforms A vector, a host cell and a method thereof
CN108359632A (zh) * 2018-03-30 2018-08-03 吉林冠界生物技术有限公司 Mdck细胞系、复制病毒的方法及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6747138B1 (en) 1995-04-03 2004-06-08 Regents Of The University Of Michigan Methods and compositions for regulating Fas-associated apoptosis
EP0816497A3 (en) * 1996-06-26 1999-12-22 Smithkline Beecham Corporation Human requiem polypeptide for apoptosis
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
GB9625283D0 (en) * 1996-12-04 1997-01-22 Janssen Pharmaceutica Nv Vertebrate homologues of unc-53 protein of c.elegans or functional eqivalents thereof and cdna sequences coding for said homologue
US20040143111A1 (en) * 1997-04-17 2004-07-22 Incyte Corporation Novel apoptosis-associated protein
US6451759B1 (en) 1998-01-14 2002-09-17 The Regents Of The University Of California Noncleavable Fas ligand
US6683168B1 (en) 1998-04-21 2004-01-27 Boston Medical Center Corporation Genes and methods that modulate apoptosis
WO1999053743A2 (en) * 1998-04-21 1999-10-28 The Trustees Of Boston University Novel genes and methods that modulate apoptosis
US6015712A (en) * 1999-07-19 2000-01-18 Isis Pharmaceuticals Inc. Antisense modulation of FADD expression
AU7614600A (en) 1999-09-27 2001-04-30 Genentech Inc. Methods for making recombinant proteins using apoptosis inhibitors
US7575860B2 (en) * 2000-03-07 2009-08-18 Evans David H DNA joining method
US20040023385A1 (en) * 2002-08-05 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of requiem expression
US7326768B2 (en) * 2003-02-05 2008-02-05 Juan Saus Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
CN1548054A (zh) * 2003-05-08 2004-11-24 陆爱丽 预防或治疗sars冠状病毒的药物

Also Published As

Publication number Publication date
CN101875957A (zh) 2010-11-03
EP2298889A1 (en) 2011-03-23
US20110129927A1 (en) 2011-06-02
US20110318316A1 (en) 2011-12-29
IL183361A0 (en) 2007-09-20
US20080295190A1 (en) 2008-11-27
CN101133156A (zh) 2008-02-27
AU2005322686B2 (en) 2012-01-19
WO2006071200A2 (en) 2006-07-06
EP2298887A1 (en) 2011-03-23
WO2006071200A3 (en) 2007-01-25
EP2298890A1 (en) 2011-03-23
JP2008526200A (ja) 2008-07-24
KR20070082597A (ko) 2007-08-21
EP2298888A1 (en) 2011-03-23
SG158841A1 (en) 2010-02-26
AU2005322686A1 (en) 2006-07-06
US20110318831A1 (en) 2011-12-29
US7846894B2 (en) 2010-12-07
CN101875692A (zh) 2010-11-03
EP1831366A2 (en) 2007-09-12
EP1997890A1 (en) 2008-12-03
US20110318317A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
US7846894B2 (en) Chinese hamster apoptosis-related genes
US6943150B1 (en) Survivin, a protein that inhibits cellular apoptosis and its modulation
US8003347B2 (en) Nucleic acids encoding ChemerinR ligands
US20100009345A1 (en) Compositions and methods comprising a ligand of chemerin R
Holmgreen et al. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members
US20090170165A1 (en) Method for recombinant production in cho cells
JP2004138610A (ja) Ａ−３３関連抗原およびそれらの薬理学的使用
JP2001522584A (ja) Ａｐｏ−３リガンドポリペプチド
US6570002B1 (en) Inhibitor of programmed cell death
JP4314386B2 (ja) Ｂｃｌ−２調節因子（ＢＭＦ）配列及びアポトーシスの調節におけるそれらの使用
JP2011246495A (ja) 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
AU749896B2 (en) Methods and reagents for modulating apoptosis
KR20010085816A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
MXPA98003883A (en) Chemiocine from pancreas de melitus de diabetes that does not depend on insul

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111005

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20111005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120904

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120911

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150921

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees